Breaking News Instant updates and real-time market news.

BCRX

BioCryst

$2.03

0.33 (19.41%)

16:51
11/19/19
11/19
16:51
11/19/19
16:51

Point72 reports 6.1% passive stake in BioCryst

Point72 disclosed a 6.1% stake in BioCryst, which represents over 9.35M shares. The filing does not allow for activism.

  • 02

    Dec

BCRX BioCryst
$2.03

0.33 (19.41%)

11/06/19
PIPR
11/06/19
NO CHANGE
Target $10
PIPR
Overweight
Piper says BCX7353 'viable,' BioCryst not getting credit for rest of pipeline
Piper Jaffray analyst Tyler Van Buren said following the presentation of new data showing that BCX7353 continues to show sustained efficacy through 48 weeks, he believes BCX7353 is an "approvable, viable" product that is also demonstrating durability. BioCryst also has several other products in the pipeline - such as BCX9930 and BCX9350 - are receiving no value from investors, added Van Buren, who keeps an Overweight rating and $10 price target on the shares.
11/15/19
BOFA
11/15/19
UPGRADE
BOFA
Buy
BioCryst upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill upgraded BioCryst to Buy from Neutral.
11/15/19
BOFA
11/15/19
UPGRADE
Target $4
BOFA
Buy
BioCryst upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad upgraded BioCryst to Buy from Neutral but lowered his price target to $4, down from $5. The analyst says that he has conducted doctor checks after the release of the ApeX-2 study results in hereditary angioedema earlier this year to determine whether his peak sales estimates for the HAE market for '7353 seemed reasonable. Ahmad notes that while the doctors still gave preference to Takeda's Takhzyro as the best option given its superior efficacy and infrequent dosing, they also expressed interest in '7353 thanks to its oral dosing convenience. Ahmad adds that he has been on the sidelines on BioCryst because of its funding needs, but sees this week's $55M equity raise boosting its cash cushion.
11/15/19
11/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying much of Qualcomm's 4G handset risk is "in the rear view mirror," and the company is positioned well for 5G ramps in 2020 and 2021. 2. Applied Materials (AMAT) upgraded to Buy from Neutral at Nomura Instinet with analyst David Wong saying the copay last night reported sales for the October quarter that were above the original guidance midpoint, and guidance for the January 2020 quarter was meaningfully above consensus estimates. 3. GrubHub (GRUB) double upgraded to Overweight from Underweight at Barclays with analyst Deepak Mathivanan saying shares of GrubHub declined by 75% in 15 months given an "irrational" competitive landscape, "ill-timed" strategic investments, and poor execution. 4. BioCryst (BCRX) upgraded to Buy from Neutral at BofA/Merrill with analyst Tazeen Ahmad saying he has conducted doctor checks after the release of the ApeX-2 study results in hereditary angioedema earlier this year to determine whether his peak sales estimates for the HAE market for '7353 seemed reasonable. 5. Nvidia (NVDA) upgraded to Buy from Hold at Craig-Hallum with analyst Richard Shannon citing the company's "strong" Q3 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.